Skip to main content

Table 1 Baseline demographic and clinical characteristics of enrolled patients with mCRC

From: Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer

Characteristic

No. of patients [cases (%)]

Sex

 Male

27 (67.5)

 Female

13 (32.5)

ECOG PS

 0

15 (37.5)

 1

25 (62.5)

Primary disease site

 Colon

23 (57.5)

 Rectosigmoid colon

1 (2.5)

 Rectum

16 (40.0)

Primary tumor resection

 No

7 (17.5)

 Yes

33 (82.5)

Adjuvant chemotherapy

 No

24 (60.0)

 Yes

16 (40.0)

Differentiation

 Well

1 (2.5)

 Moderate

29 (72.5)

 Poor

3 (7.5)

 Unknown

7 (17.5)

Metastatic sites

 Liver

24 (60.0)

 Lung

16 (40.0)

 Lymph nodes

10 (25.0)

 Peritoneum

8 (20.0)

 Others

4 (10.0)

No. of metastatic sites

 1

14 (35.0)

 2

18 (45.0)

 ≥3

8 (20.0)

  1. mCRC metastatic colorectal cancer, ECOG Eastern Cooperative Oncology Group, PS performance status